(CNSNews.com) - Housing and Urban Development Director Dr. Ben Carson told Fox News Wednesday night that President Donald Trump is right to focus on Americans' health as well as their economic future. Both have life-or-death consequences, he said.
The pandemic "is transient," Carson noted:
This too will pass. What we have to do is be smart enough to make sure we keep all of our infrastructure, our economic infrastructure intact so we don't have to start all over again.
I think the president has recognized that. There are many people who criticize him for being concerned about the economy, but the fact of the matter is if we don't have an economy by the time we get done with this, we are in terrible shape and a lot of people will die from that. So we have to be able to look at both things, walk and chew gum at the same time.
Carson said that he (like the president), is "hopeful, obviously, that we can get back to work as soon as possible, but it will probably be phased.
"There are some people who are not at great risk; there are some people who already have had the disease and therefore have the antibodies. These are people who probably can start going back to work. We need to talk about this and deal with it in a logical and reasonable way."
On another hopeful note, Dr. Ben Carson discussed an experimental procedure, just approved by the Food and Drug Administration, that is now being tried out in New York.
It involves taking plasma from people who have recovered from coronavirus and therefore have the antibodies, then injecting that plasma into people who are critically ill with the disease.
"It has worked in the past, more than 100 years ago during the 1918 flu epidemic that was going on here, it was utilized successfully. More recently, in 2002 during the SARS outbreak, it cut down on the severity and the duration of symptoms," Carson said:
It is promising -- the concept actually makes a lot of sense. If you had it and you've gotten over that, than obviously your immune system has kicked in and you have some significant antibodies against the viral antigen and those tend to last much longer than the antigen does, and therefore if you can transfer that -- that's going to require significant coordination with the blood banks, because they have to type the plasma and various things like that but we should be able to get some very quick results.
This was just approved yesterday. The FDA has been doing a yeoman's job, and there are more than 100 different therapies being looked at right now. I think we are going to come up with something.